Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Arthritis, Rheumatoid × RC-18 × Clear all

Phase

Phase 3 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, Follicular 1 Arthritis, Rheumatoid 1

Interventions

Methotrexate 4 Abatacept 3 tocilizumab 2 Rituximab 2 tofacitinib 1 secukinumab 1 olokizumab 1 golimumab 1 baricitinib 1 Radioimmunodetection 1 RC-18 1 Etanercept 1 Double-Blind Method 1 Certolizumab Pegol 1 Antirheumatic Agents 1 Adrenal Cortex Hormones 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03016013 2024-09-26

A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects with Inadequate Response to MTX Due to Treat Moderate and Severe Rheumatoid Arthritis.

RemeGen Co., Ltd.

Phase 3 Completed

Arthritis, Rheumatoid, Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon ⚡